KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Accumulated Expenses (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Accumulated Expenses data on record, last reported at $11.9 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 17.51% year-over-year to $11.9 million; the TTM value through Dec 2025 reached $11.9 million, up 17.51%, while the annual FY2025 figure was $11.9 million, 17.51% up from the prior year.
  • Accumulated Expenses reached $11.9 million in Q4 2025 per RIGL's latest filing, up from $10.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $11.9 million in Q4 2025 and bottomed at $5.2 million in Q1 2024.
  • Average Accumulated Expenses over 5 years is $8.1 million, with a median of $7.9 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: dropped 17.06% in 2022, then grew 27.02% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $10.7 million in 2021, then fell by 17.06% to $8.9 million in 2022, then decreased by 2.14% to $8.7 million in 2023, then increased by 16.86% to $10.1 million in 2024, then grew by 17.51% to $11.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $11.9 million in Q4 2025, $10.1 million in Q3 2025, and $7.9 million in Q2 2025.